Table 3.

Factors associated with accepting treat to target approach

	Treat to target not accepting	Treat to target accepting	Univariate analysis	Binary logistic regression
Diagnosis (n)
CD	54	90		B=−1.28
UC	38	98
IBD-U	8	10	p=0.2	p=0.021
IBD-related surgery (n)				B=0.95
Yes	18	52
No	82	146	p=0.2	p=0.08
Mesalazine treatment (n)
Never	26	45		B=−0.49
Previous	34	61
Current	40	92	p=0.7	p=0.3
Thiopurine treatment (n)
Never	38	72		B=0.3
Previous	33	64
Current	29	62	p=0.9	p=0.5
First-line anti-TNF treatment (n)
Never	67	126		B=−0.56
Previous	20	25
Current	13	47	p=0.08	p=0.3
Second-line anti-TNF treatment (n)
Never	84	186		B=0.63
Previous	1	6
Current	12	6	p=0.012	p=0.4
Disease duration (median in years, not normally distributed)	7	8	p=0.4	B=−0.004 p=0.9
Age (mean in years, normally distributed)	44.7	48.7	p=0.07	B=−0.006 p=0.7
Patient knowledge (mean, normally distributed)	4	4	p=0.09	B=0.66 p=0.5
CRP (available for 281 patients, median, not normally distributed)	1	1	p=0.7	B=0.59 p=0.1
FC (186 samples returned, median, not normally distributed)	104	111	p=0.7	B=0 p=0.4
Patient-reported current disease control (10-point Likert scale, median, not normally distributed)	9	8	p=0.6	B=0.13 p=0.6
Patient-reported 3-year disease control (10-point Likert scale, median, not normally distributed)	7	7	p=0.6	B=0.04 p=0.6
HADS anxiety (median, not normally distributed)	8	7	p=0.2	B=−0.26 p=0.8
HADS depression (median, not normally distributed)	7	6	p=0.4	B=−0.13 p=0.2
Medication adherence (MARS, median, not normally distributed)	19	20	p=0.032	B=0.16 p=0.039
Quality of life (SIBDQ, median, not normally distributed)	54	56	p=0.4	B=−0.55 p=0.1

CD, Crohn’s disease; FC, faecal calprotectin; HADS, Hospital Anxiety and Depression Scale; IBD, inflammatory bowel disease; MARS, Medication Adherence Report Scale; NB, where figures do not add up to 298 the relevant status was not known for some patients; SIBDQ, Short IBD Quality of Life Questionnaire; TNF, tumour necrosis factor; UC, ulcerative colitis.